SAM
ABCL icon

SEB Asset Management’s AbCellera Biologics ABCL Stock Holding History

SEB Asset Management’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-340,267
Closed -$1.19M – 701
2026
Q1 		$1.19M Buy
+340,267
New +$1.22M 0.01% 611

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

SEB Asset Management's ABCL Position: Q2 2026 in Review

SEB Asset Management sold out of AbCellera Biologics (ABCL) in Q2 2026, closing a stake of 340,267 shares — an estimated $1.19M sold.

SEB Asset Management first reported a position in ABCL in Q1 2026 and held it in 1 quarter. The position peaked at $1.19M in Q1 2026. 142 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • SEB Asset Management reported no remaining AbCellera Biologics position as of Q2 2026 after selling out during the quarter.
  • SEB Asset Management sold 340,267 AbCellera Biologics shares in Q2 2026, an estimated $1.19M.
  • SEB Asset Management first reported a position in AbCellera Biologics in Q1 2026 and held it in 1 quarter.
  • SEB Asset Management's AbCellera Biologics position peaked at $1.19M in Q1 2026.
  • 142 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on SEB Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.